Welcome to our dedicated page for Galecto SEC filings (Ticker: GLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drug discovery moves quickly, but decoding the paperwork rarely does. Galecto’s breakthroughs on galectin-3 and LOXL2 generate dense SEC disclosures packed with trial data, milestone payments and collaboration terms. If you have ever asked “what does Galecto report in its 10-K?” or searched for “Galecto insider trading Form 4 transactions,” you know the challenge of extracting what matters from hundreds of pages.
Stock Titan removes that friction. Our AI engine reads every submission the moment it reaches EDGAR, delivering plain-English highlights of each “Galecto quarterly earnings report 10-Q filing” and alerting you to “Galecto Form 4 insider transactions real-time.” Need a quick brief on a surprise 8-K? Select “Galecto 8-K material events explained” and let the platform surface the key clinical or financing update in seconds. The result is “Galecto SEC filings explained simply,” giving you more time to evaluate science instead of syntax.
Because Galecto’s value hinges on clinical progress, we link risk factors in the “Galecto annual report 10-K simplified” to pipeline milestones, map 10-Q cash-burn tables to trial timelines, and flag royalty clauses hidden in exhibits. Use our tools to:
- Monitor “Galecto executive stock transactions Form 4” ahead of catalyst dates
- Run a “Galecto earnings report filing analysis” to compare R&D trends with study results
- Review the “Galecto proxy statement executive compensation” structure beside performance goals
Whether you’re “understanding Galecto SEC documents with AI” for the first time or tracking every “Galecto insider trading Form 4” alert, Stock Titan delivers real-time coverage, expert context and AI-powered clarity—so you can focus on assessing fibrosis and oncology breakthroughs, not deciphering legal prose.
Federal Signal Corp. (FSS) – Form 4 filing (06/30/2025)
Director Katrina L. Helmkamp reported an acquisition of 131 common shares on 06/27/2025 (Transaction Code A). The form lists a transaction price of $0.00, implying the shares were received through a non-cash award (e.g., director equity grant). Following the transaction, Helmkamp’s direct holdings increased to 4,326 shares. No derivative security activity was reported.
The filing represents a routine, immaterial change in individual ownership and does not disclose any broader corporate events, financial results, or derivative transactions.
Galecto, Inc. (GLTO) – Form 4 insider filing
On 18 June 2025, non-employee director Dallas Jayson Donald Alexander received an automatic grant of 720 stock options under the company’s Director Compensation Policy. The options carry an exercise price of $3.22 per share, a 10-year term expiring 18 June 2035, and will vest in equal monthly installments over one year. The filing lists the director’s ownership as direct and discloses no sales or other equity transactions.
Given the small size of the grant and its routine nature, the disclosure is unlikely to have a material impact on Galecto’s valuation or trading dynamics; however, it does incrementally align director incentives with shareholder value through equity-based compensation.
Galecto (NASDAQ: GLTO) submitted a routine Form 4 detailing a small insider equity grant.
On 18 June 2025, director Amit Munshi received a stock option for 720 common shares at an exercise price of $3.22 per share. The grant was issued under the company’s Non-Employee Director Compensation Policy in conjunction with the 2025 Annual Meeting. The option vests in equal monthly installments over one year and expires on 18 June 2035. Following the transaction, Munshi beneficially owns 720 derivative securities; no non-derivative share holdings were reported.
The filing is administrative in nature, disclosing routine director compensation with no material impact on Galecto’s financial position or governance profile.
Galecto (NASDAQ:GLTO) filed a routine Form 4 reporting that director David Shapiro received a stock option for 720 common shares at an exercise price of $3.22 on June 18, 2025. The award was granted under the company’s Non-Employee Director Compensation Policy and will vest in equal monthly installments until the first anniversary of the grant date. No shares were sold or otherwise disposed of, and Shapiro now directly holds 720 derivative securities following the reported transaction.
Galecto (NASDAQ:GLTO) filed a routine Form 4 disclosing that director Anne Prener received an automatic equity award under the company’s Non-Employee Director Compensation Policy.
On 18 June 2025, Prener was granted 720 non-qualified stock options with an exercise price of $3.22 per share. The options vest in equal monthly instalments over 12 months and expire on 18 June 2035. No common shares were sold or otherwise disposed of, and her beneficial ownership now reflects the 720 newly issued options. The filing contains no other transactions, sales, or material amendments.
On 25 June 2025 Turkcell İletişim Hizmetleri A.Ş. (NYSE: TKC) reported via Form 6-K that its Board authorized two short-term sukuk programs totalling TRY 4.5 billion. The telecom’s payments subsidiary, Turkcell Ödeme ve Elektronik Para Hizmetleri A.Ş., may issue up to TRY 2 billion management-agreement based lease certificates, while the financing subsidiary, Turkcell Finansman A.Ş., may issue up to TRY 2.5 billion commodity-trading based lease certificates. Both instruments will be placed domestically, without public offering, to qualified or institutional investors and carry maturities of up to 12 months. Each issuance requires prior approval from Türkiye’s Capital Markets Board. The move expands Turkcell’s near-term funding flexibility and diversifies its capital structure without immediate equity dilution.
Columbia Short Duration Bond ETF (symbol SBND) submitted a Form NPORT-P, the SEC’s required monthly portfolio investments report. The filing includes all standard sections—Filer Information, Part A (registrant and series details), Part B (fund-level assets, liabilities, risk metrics, securities-lending activity, monthly returns and share flows), and related schedules. However, every quantitative field—total assets, liabilities, net assets, DV01/DV100 risk metrics, credit-spread sensitivities, securities-lending details, monthly performance, and share sales/redemptions—remains blank in the excerpt provided. Contact information, CIK, LEI and series identifiers are likewise missing. The only populated item is the “LIVE” filing status, and the fund does not mark the report as a final filing. Because the data cells are empty, the document offers no insight into SBND’s portfolio composition, risk profile, or recent performance and therefore has limited immediate analytical value for investors.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
What is the core focus of Galecto Inc.?
Which therapeutic targets does the company focus on?
What are some of Galecto's lead product candidates?
How does Galecto enhance the effectiveness of current cancer therapies?
In which therapeutic areas is the company developing its pipeline?
How does Galecto position itself in the competitive biotechnology landscape?
What makes the company's approach to drug development unique?
Are there any collaborations or trial initiatives associated with Galecto?
